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Abstract 
Oral administration of drugs is most convenient for patients and therefore, the ultimate goal when 
developing new medication. The physical barriers in the body, low pH of the stomach and degradation by 
enzymes in the gastrointestinal tract are a few of the obstacles for succeeding with oral drug delivery. 
Microfabricated devices show promise to overcome some of these hindrances and thereby improving the 
bioavailability of drugs after oral administration. There is an increasing focus on microfabricated oral drug 
delivery systems, and so far there are three main groups of designs; patch-like structures, microcontainers 
and microwells. Here, we review the newest development in top-down microfabricated devices for oral 
drug delivery with coverage of the aspects of design, choice of material and fabrication techniques. 
Furthermore, the drug loading techniques and methods for testing are discussed. In addition, we discuss 
the future perspectives for microfabricated devices.  
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Introduction 
Oral delivery is the preferred administration route for drugs due to its minimally invasive nature and 
convenience for the patients. However, it has key challenges and limitations: (i) Many potent drugs such as 
proteins and peptides (e.g. insulin) are unable to survive the passage through the gastrointestinal (GI) tract. 
They are enzymatically degraded, hydrolyzed and/or chemically deactivated in the acidic gastric 
environment. Further, the physical barriers in the intestine either destroy the macromolecules or prevent 
their absorption1. The GI tract is coated by a 100 µm thick mucus layer, and the drug needs to pass the 
mucus layer and subsequently, cross the epithelial cell layer to be absorbed in the body and distributed via 
the blood circulation. (ii) The release kinetics need to be controlled (time, location and amount). Some 
drugs need to be delivered in a ‘burst mode’ at a specific site, whereas others need to be released in a 
more controlled manner over larger parts of the GI tract. (iii) Up to 90 % of the drugs in development 
display low solubility in the intestine and furthermore, a great portion of these have poor intestinal 
permeability2,3. This means that a large fraction of the drug is wasted since it is simply not dissolved in the 
intestinal fluids and thereby is unavailable for absorption at the intestinal wall. As a result, the oral 
bioavailability of the drug is compromised. 
 
Today, oral drug dosage forms are primarily produced by powder technology and compressed into tablets. 
For decades, particle technologies have existed and these enable the production of drug formulation 
containing micro- and nanoparticulates from a variety of polymers4,5. Such formulations have, due to their 
spherical shape, a small contact area to the intestinal wall in comparison with other shapes such as squares 
or tetrahedrons6,7. Moreover, particles have the disadvantage that they may differ in size and thus, in 
loaded amount of drug. Lately, microdevices have been suggested as possible oral drug delivery vehicles8,9. 
A schematic drawing of a microfabricated drug-carrying device is shown in Figure 1, where the essential 
features are highlighted. It is speculated that these devices provide a unidirectional drug release since only 
one face of the drug reservoir can open and due to the integration of chemical or structural cues to 
promote oriented adhesion to the intestine wall. In this way, it might be possible to limit loss of the drug to 
the surroundings, as illustrated in Figure 1.  
Another hypothesis is that these microfabricated devices can protect drugs until their final destination of 
delivery. It is anticipated that the unidirectional release as well as a sustained resident time due to mucus 
attachment or penetration will allow more drug to be absorbed. Indeed, the transfer of drug across an in-
testinal epithelial cell monolayer has been seen to increase by a factor of ten using such microdevices10. 
Initial animal studies have also been published10–12 showing an increase in oral bioavailability. 
 
The concept of microfabricated devices for oral drug delivery has been discussed in several other review 
papers13–16. In this review, we focus on the latest developments in top-down microfabricated devices for 
oral drug delivery. More conventional fabrication technologies, such as microparticle realization, and larger 
devices such as intelligent pills or 3D printed mm-sized tablets are not included. We will in the following 
cover the aspects of design, fabrication and material choice, loading of active pharmaceutical ingredients 
(APIs) and in vitro and in vivo testing.  
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Design 
The general design concept for microfabricated devices for oral drug delivery is the same: Drug is enclosed 
in a micro-reservoir to protect it from the environment until release of the drug is desired (often in the 
small intestine). However, the dimensions of the devices are different and they include more or less of the 
different key features highlighted in Figure 1.  
The design of the microdevices is closely related to the available fabrication technologies. Also, the design 
has an influence on flow behavior of the device in the GI tract, adhesion or penetration through the mucus 
layer, amount of loaded drug and number of different drugs to be delivered simultaneously/sequentially. 
An overview of different realized designs is shown in Table 1, with a classification into patches, containers 
and wells. 
The patch-like structures have a low aspect ratio, with typical thickness of a few µm and lateral dimensions 
of more than 50 µm. Such designs have been highlighted to improve mucoadhesion because they have a 
low flow resistance17 and can easily contain several compartments for different drugs. Microcontainers 
have a higher aspect ratio, with height and diameter of similar dimensions, typically around 100-300 µm. 
The microcontainers can in general carry a higher load of drugs and have been reported to display 
mucoadhesive capabilities11. To fully protect the loaded cargo, the microcontainers can be sealed with a lid 
of e.g. a pH-sensitive polymer to facilitate release in certain regions of the GI tract11,12,18,19. More advanced 
designs have been proposed, where the microdevices are processed as two dimensional objects and then 
self-fold into container structures upon exposure to liquid20. In addition, primarily for proof-of-concept 
studies, microwells have been reported18. The microwells are formed as indentations in a surface and can 
be used to study e.g. drug loading technologies. A few examples of surface texturing of microcontainers 
have been published21. There, the general idea is to enhance the adhesion to the epithelial wall and 
potentially also to change the release profile of loaded drugs by applying e.g. hollow nanostructures on one 
side of microdevices.  
Microdevices for oral drug delivery are still on a proof-of-concept level, and therefore the optimal design 
for achieving the best system promoting drug delivery and unidirectional release at the intestine wall still 
needs to be identified. For now, only few attempts to identify the optimal design have been made and 
comparative studies with various designs of microdevices are still lacking.   
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Figure 1: Left: Spherical particles release drugs in all directions, which is highly inefficient. A container 
structure might ensure unidirectional release of drug(s). Right: Schematic illustration of microfabricated oral 
drug delivery device and an indication of possible key features of the device; outer geometry, inner drug 
reservoir design, lid, surface structuring and surface functionalization. 
 
Table 1: Overview of design, microfabrication technologies and materials for oral drug delivery devices 
Design Drug delivery devices Fabrication method Materials References 
 
Micropatches (single and multi-
compartment) 
Photolithography and 
etching 
SiO2, PMMA 
22–24 
 
Micropatches and 
microcontainers 
Photolithography SU-8 25,26 
 
Micropatches, self-foldable 
microparticles 
Soft lithography PLGA, PEGDA, 
PEGDMA 
20,26 
 
Microwells Hot embossing PLLA, PCL 18,27 
 
 
Microcontainers Mechanical punching PLLA 28 
 
 
Microcontainers Hot punching PLLA, PCL 29 
 
 
Sealed microcontainers Spray coating Eudragit L100 11,12,18 
 
Sealed microcontainers Thermal bonding PLGA, PC, 
PMMA 
21,30 
 
 
 
Microfabrication technologies and materials 
The first approaches for top-down microfabrication of oral drug delivery devices have been based on 
traditional methods such as photolithography and etching developed by the electronics industry. An 
overview of the reported methods used for fabrication of the devices can be seen in Table 1 and Figure 2. 
In 2001, Ahmed et al. presented initial studies on fabrication of rectangular micropatches with drug 
reservoirs23,31. The fabrication technology combines thin film deposition methods, photolithography and 
etching to define patches in SiO2 (Figure 2A). The patches have a height of a few µm, lateral dimensions of 
50-150 µm and contain single or multiple compartments providing volumes of 5-10 pL. A similar approach 
combined with electrochemical anodization has been introduced for the fabrication of porous silicon 
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microparticles24. Tao et al. have proposed the fabrication of polymer micropatches using 
polymethylmethacrylate (PMMA) (Figure 2A)22. This material has the advantage that it is biocompatible, 
already employed in many biomedical applications and suitable for surface functionalization. 
Photolithography combined with reactive ion etching has been used to define the patches. As a major 
drawback, the methods for fabrication of Si, SiO2 and PMMA micropatches involve a large number of 
processing steps and the reservoir depth is limited to a few µm. 
In 2005, the same research group26,32 demonstrated fabrication of micropatches with a height of 8-12 µm 
using several steps of photolithography with the negative epoxy photoresist SU-8 (Figure 2B). The 
advantages of this method are that etching steps and secondary materials for patterning (photoresists, etch 
masks) can be avoided and that fabrication of devices with higher reservoir depth is relatively 
straightforward. For example, Nielsen et al.25 have used two steps of photolithography for the preparation 
of SU-8 microcontainers with lateral dimensions of 300 µm, a reservoir depth of 270 µm and drug volumes 
of about 10 nL (Figure 2B). SU-8 is a suitable material for prototyping and initial proof-of-concept. However, 
the main drawback is that it is that is an epoxy based resin and potential accumulation in the GI tract could 
lead to unwanted side effects. 
Therefore, several methods for fabrication of drug delivery devices using biodegradable polymers have 
been proposed26,27,29. Tao et al. have used soft lithography with SU-8 microstructures to prepare PDMS 
masters and subsequently performed microtransfer molding to define microwells in poly(lactic-glycolic 
acid) (PLGA) and gelatine (Figure 2C)26. Nagstrup et al.27 have demonstrated the fabrication of microwells in 
biodegradable polymers poly(L-lactic acid) (PLLA) and poly(caprolactone) (PCL) by hot embossing. The 
stamps have been prepared by SU-8 photolithography and later replaced by electroplated Ni18. A major 
challenge with these traditional polymer replication methods is that a thin residual polymer layer connects 
the individual microwells after completed molding. This polymer film can eventually be removed by 
reactive ion etching or reduced by applying very high pressure during the embossing process. However, this 
requires either additional process steps or advanced processing equipment.  
To address this issue, Petersen et al. have recently presented two approaches for fabrication of individual 
biodegradable polymer microcontainers based on mechanical punching (Figure 2D)28 and hot punching 
(Figure 2E)29. In the latter, a soft PDMS layer is introduced between the biodegradable polymers and the Si 
substrates. This provides the necessary elastic force during the hot embossing process to allow penetration 
of the thin residual layer. The microcontainers obtained with this method have a width of 300 µm and a 
height of 100 µm. Alternatively, self-folding hydrogel microparticles have been fabricated and proposed as 
microdevices for oral drug delivery20. Soft lithography has been used for the fabrication of micropatches 
with lateral dimensions of 50-100 µm, a height of 7-10 µm and a volume of a few pL. More specifically, 
resins of poly(ethylene glycol methacrylate) (PEGMA) and poly(ethylene glycol dimethacrylate) (PEGDMA) 
have been cast on PDMS stamps filling the stamp structures. With this approach, the residual layer typically 
connecting individual microdevices is avoided due to discontinuous dewetting of the PDMS mold used for 
casting of the polymers.  
Several other methods have been introduced for fabrication of microdevices for applications in drug 
delivery. For example, mesoporous Si-based microparticles have been prepared by etching33,34 and 
monodisperse polymeric particles have been fabricated by particle replication in non-wetting templates 
(PRINT)35,36 or hydrogel templating37,38. However, although a future application of these microdevices for 
oral delivery can be possible, most of these studies have focused either on intravenous delivery or more 
fundamental aspects related to microfabrication. 
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Most of the fabrication methods discussed above provide no or incomplete encapsulation of the drug. For 
development of a complete oral drug delivery system, the drug should be protected through the stomach. 
Therefore, a pH-sensitive coating, dissolving when the microdevices reach the pH of the intestine (pH 6-7), 
is often desirable39. To date, only a few methods for microfabrication of devices for oral drug delivery with 
completely sealed drug reservoirs have been developed. Recently, spray coating has been introduced for 
the deposition of Eudragit L100 or S100 films on SU-8 and biopolymer microcontainers loaded with drug 
(Figure 2B)12,18,19. These polymer lids are stable in simulated gastric medium (pH 2) and dissolve upon 
immersion in simulated intestinal medium (pH 6.5), triggering release of the drug. The advantage of this 
method is that spray coating potentially is scalable. As a drawback, the deposition method is not selective, 
meaning that polymer is spray coated everywhere on the sample. This can be circumvented by the 
implementation of a shadow mask40. 
 
Alternatively, several approaches of thermal bonding of polymer layers for encapsulation of drug in 
microfabricated devices have been demonstrated. Fox et al. have deposited membranes made of 
polycarbonate (PC) onto PMMA-PCL microcontainers using heat assisted bonding21. Aluminum oxide 
nanostraws have been integrated in the PC membranes providing nanochannels for drug loading and drug 
release. More recently, sealing of PLGA microcontainers with thermally bonded lids has been demonstrated 
with a process defined as stamped assembly of polymer layers (SEAL) (Figure 2F)30. This method allows for 
selective deposition of membranes on the drug delivery microdevices. However, equipment for precise 
alignment and bonding of lid and drug reservoirs is required.  
 
One of the challenging aspects in top-down fabrication of drug delivery microdevices is their release from 
the carrier substrate and subsequent harvesting at the end of the drug loading process. Several methods 
involving wet chemistry for removal from the Si substrate have been proposed, such as simple 
delamination upon immersion in basic solution41, etching of a sacrificial layer in KOH23 or dissolution of a 
release layer in organic solvents42. More recently, poly(acrylic acid) (PAA) and PAA-PEG have been 
introduced as water soluble sacrificial layers for fabrication of SU-8 and biopolymer microcontainers12,29. 
Hereby, it is possible to avoid the use of aggressive etchants or solvents that potentially can affect the drug 
delivery devices and/or the loaded drugs. To completely prevent initiation of drug release, dry processes 
have been established such as simple mechanical removal of devices from fluorocarbon coated carrier 
substrates using razor blades8,11.  
 
At present, SU-8 based or PMMA based microcontainers fabricated by traditional microfabrication methods 
are still very well suited for initial proof-of-concept studies. However, the authors believe that fabrication 
of these microdevices in biodegradable polymers is a necessary and significant step in the direction of 
bringing microdevices for oral drug delivery onto the market. There is still a long way to go in terms of 
fabrication, and also the first steps of incorporating drugs and depositing lids on the microdevices are very 
essential for this development. 
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Figure 2: Schematic showing the relevant fabrication methods for drug delivery devices and with SEM 
images as examples of the fabricated microdevices. 
 
Loading of Active Pharmaceutical Ingredients  
After fabrication of the microdevices, it is essential to load them in an efficient way with API (Figure 3). The 
optimal method should allow for parallel loading of large numbers of microdevices with identical amounts 
of drug while providing minimal drug waste. Based on our experience, reproducible loading of API into the 
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small drug reservoirs is one of the most challenging aspects in preparation of microfabricated drug delivery 
devices. 
In initial attempts to load Si micropatches, microinjection has been used to inject biopolymer compounds 
dissolved in an aqueous solution into microcontainers31,43. After this, inkjet printing of solutions has been 
evaluated on several occasions (Figure 3A)31,43,44. Despite these attempts, the printing technique has not 
been established as the preferred method for direct loading of drug. The main challenges with this method 
are limitations on the solvents and the viscosity, which results in that the drug content in the solutions that 
can be printed, is relatively low. This means that multiple cycles of deposition and drying have to be 
performed which together with the fact that inkjet printing typically is a serial process results in a very low 
throughput. It could in addition also have the consequence that many more microdevices would need to be 
administered to the patient leading to higher costs of the medicine.  
Alternatively, Marizza et al. used inkjet printing to load PVP solutions into SU-8 microcontainers. It has been 
possible, in a reproducible manner, to print up to 20 wt%  polymer in aqueous solution44, directly into the 
microcontainers. Subsequently, the PVP has been impregnated with ketoprofen by supercritical CO2 
impregnation (Figure 3B)45. This method has the advantage that organic solvents can be avoided and that 
drug waste can be minimized. The drawback is that the throughput of inkjet printing is low if a single nozzle 
is used for dispensing. Therefore, PVP has also been loaded manually as a powder and then impregnated12. 
This speeds up the loading process significantly. Optimization of pressure, temperature and time during 
impregnation resulted in a drug loading of more than 1 µg in each microcontainer (Figure 3B)46. A benefit of 
the supercritical CO2 impregnation is that ketoprofen is converted to its amorphous form during 
impregnation12,45. Ketoprofen is poorly soluble in water, and therefore it is highly advantageous to have the 
drug in its amorphous form since this will greatly enhance solubility and dissolution rate of the drug47.     
 
Drug-laden hydrogels have frequently been exploited for their application as an oral drug delivery system. 
Prepared hydrogels containing an API, e.g. fluorescein isothiocyanate (FITC)-albumin, have been spin 
coated into empty patches followed by selective UV photolithography to confine hydrogel areas within the 
reservoirs of the micropatches (Figure 3C)6,17. A similar method has been applied with the small drug 
molecule, acyclovir. Here, drug-hydrogel  has been loaded into micropatches with three reservoirs resulting 
in a load of approximately 1.5 ng of acyclovir per reservoir (Figure 3C)10. The same method has also been 
used to add several drug layers on top of each other inside micropatches, hereby obtaining sequential 
(layer-by -layer) drug release6,17. 
Drug-hydrogel layers are very useful when a prolonged drug release is needed. API needs to diffuse through 
the hydrogel matrix, thereby delaying the release of drug from the devices. Another advantage of using UV 
photolithography is that large arrays of microdevices can be loaded with drug in a single step. Spin coating 
has the disadvantage of relatively large waste in the process. Moreover, the maximum achievable drug 
concentration in the hydrogel matrix can be low and UV radiation and crosslinking of the hydrogel can 
potentially affect the API.  
  
In a study by Guan et al., an aqueous solution of the model drug, sodium chloride (NaCl) has been brushed 
into microdevices, and when the solvent evaporated, NaCl crystals were formed20. This method can be 
performed with low waste and is therefore, very beneficial when loading biopharmaceuticals into 
microdevices. The methods described until now have mostly been handling liquid samples, but many drugs 
are available in powder form and have increased stability when handled as powder, e.g. amorphous drugs 
9 
 
and biopharmaceuticals. It is therefore relevant to load the microdevices with a powder. Previously, a 
modification of a screen printing method has been used to load microwells with an amorphous drug 
powder18. The screen is applied to prevent deposition of drug powder in the area between the microwells. 
After alignment of the screen to the cavity of the microwells, the drug powder is distributed followed by 
removal of the screen. This process has resulted in filled microwells with no drug distributed between 
them18. However, the alignment of such a screen is time consuming which prevents high-throughput 
loading. In a faster technique, powder drug has been manually loaded into microcontainers using a spatula 
or brush followed by the use of an airgun to remove excess drug in-between the microcontainers (Figure 
3D)11,25. This method is versatile and has also been used to load PVP12 and drug formulation of lipid particles 
containing ovalbumin into microcontainers 19. Typically, these methods have resulted in a minimum drug 
loading of 2 µg per microcontainer. However, the method is time consuming, the amount of loaded drug 
can vary from device to device and a considerable amount of drug is wasted. An alternative loading method 
defined as powder embossing has been developed by Abid et al. (Figure 3E)48. Here, a metal shadow mask 
is aligned and clamped to the cavity of microcontainers followed by pressing the substrate into powder of 
either drug, polymer or lipid-based microparticles. The method has been reported to have 100 % yield in 
terms of completely filling every microcontainer with powder and the throughput can be increased by 
loading drug into larger arrays of microcontainers48. Furthermore, this method has also resulted in at least 
2 µg of drug per microcontainer.    
 
Alternatively, spin coating has been used to initially form a uniform drug-polymer film which is then loaded 
into microcontainers using hot punching (Figure 3F)49. One of the main advantages of this process is the 
parallel loading of large numbers of devices in a single step with the possibility to transfer it to roll-to-roll 
(R2R) processing. Furthermore, the process is versatile and avoids alignment steps. The drawbacks are that 
punching is performed at elevated temperatures (>60°C), which might affect some drugs and that the 
amount of drug in spin coated drug polymer films can be relatively low due to limitations in solubility. 
 
It can be difficult to advice on which loading method to use as it will depend greatly on the API and thereby 
on which dose is needed to achieve a therapeutic response in animals or humans. We believe that methods 
where powders are loaded into the microdevices are very versatile and are most promising for upscaling 
and for achieving a sufficiently high dose for testing drug-filled microdevices in animals.     
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Figure 3: Graphics presenting the proposed methods for loading the fabricated microdevices with drug or 
drug formulation.   
 
In vitro and in vivo testing  
Fabrication of drug delivery microdevices is more time consuming and less cost efficient than e.g. producing 
particulates for oral drug delivery, which has been performed for decades50. To be competitive, the 
advantages obtained using microfabricated devices have to be considerable, and thorough in vitro and in 
vivo evaluation is important. In vitro studies are preferably carried out before any in vivo studies as they 
C) Photolithography6,10,17
D) Manual powder filling11,25
A) Inkjet printing31,43,44
B) CO2 impregnation
45-47
E) Powder embossing48
F) Spin coating and hot punching49
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often give a good indication on how the microdevices and the API will perform. To realize a good 
correlation between in vitro and in vivo studies, the in vitro studies should be as close to the in vivo 
situation as possible. This means that media simulating the fluids in the body and animal tissue should be 
used for in vitro, ex vivo or in situ studies.   
An overview of the methods and API’s applied for testing the fabricated microdevices is shown in Table 2. 
 
Bioadhesion 
The main goal of new oral drug delivery systems is to promote the therapeutic effect of a drug, but also to 
minimize toxic effects. This can be done by increasing the amount of drug at the target site (usually the 
small intestine) to ensure rapid drug absorption and in addition, to reduce the drug concentration at non-
target sites51. The GI transit time through the stomach and small intestine of an orally dosed device is 4-8 h 
in humans, and in many cases it is essential to prolong this time52. Therefore, one of the main aims of a 
delivery system is often adhesion to the GI tract and hence, mucoadhesion has been intensively studied51,53. 
 
The Caco-2 cell line is a commonly used intestinal cell line derived from human colonic adenocarcinoma, 
which is found to have many of the characteristics of the epithelium of the small intestine (tight junctions, 
microvilli, growth factor receptors, and major drug metabolizing enzymes)54. The Caco-2 cell line has 
become useful for investigating permeability and absorption of drugs in the development of new drug 
delivery systems54. It has also been widely used to test newly developed microdevices. Micropatches 
functionalized with tomato lectin have been incubated with Caco-2 cells to study adherence via ligand-
receptor interactions23,31. It has been found that the functionalization of the micropatches resulted in 
improved adhesion to the Caco-2 cells compared to non-functionalized devices. This has been explained by 
the flat and disc-shaped design and the small size of the micropatches 23,31.  
In the in vivo situation, there is a flow of liquid in the intestine. Therefore, it is important to study adhesion 
under flow conditions. Ainslie et al. have investigated the adhesion of micropatches functionalized with 
lectin to Caco-2 cells in a diffusion flow cell. By taking micrographs continuously during the study, the 
amount of micropatches adherent to the cells as well as the clustering effect of the microdevices have been 
investigated8. It has been found that the functionalized micropatches have a significantly higher adhesion 
(percentage of micropatches sticking to the cells) to the cells compared to non-functionalized 
micropatches, 53 % versus 6.8 %, respectively. Furthermore, the investigations have revealed that the 
orientation of the micropatches with respect to the flow have been random, but when the micropatches 
landed face down they remained attached to the Caco-2 cell monolayer during the investigated time of 30 
min8. However, a major limitation of these flow studies is the fact that presence of mucus on the cells has 
not been demonstrated, which is not completely representing the conditions in the intestine.  
 
For a better correlation to the in vivo situation, and as an improved investigation method, tissue from 
animals has been used. Gupta et al. measured the adhesive forces of mm-sized drug-polymer patches on a 
piece of porcine intestinal tissue. The patches mounted on a holder and tissue have been incubated 
together and subsequently pulled apart. The adhesive force has been quantified using a microbalance55. A 
simplified method has also been used, where self-folding microdevices have been placed on a piece of 
inclined pig intestine. Water was added followed by optical microscopy to count the amount of maintained 
microdevices and to inspect the depth of engulfment in the mucosa20. Similarly, Lee et al. investigated the 
mucoadhesion on porcine intestinal tissue in an apparatus with a tilted angle and a continuous flow of 
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simulated intestinal fluids while videos of the adhesion have been recorded53. Microcontainers have also 
been tested in a closed-loop in situ perfusion model in rats, where cannulas were inserted into the 
intestine, and through these, drug-filled microcontainers could be dosed together with fluid. After the 
study, the intestine has been removed and visualized to investigate how the microcontainers interacted 
with the intestinal membrane11.  
 
By our experience, the best experimental method for investigating bioadhesion is a method as close to the 
in vivo situation as possible. If feasible, it will be advantageous to utilize tissue instead of cell lines because 
at present most in vitro cell models still have difficulties to represent the complex structure of intestinal 
tissue and the presence of mucus.  
 
In vitro drug release from the microdevices 
In vitro drug release studies can be used to evaluate efficacy of the microdevices in carrying and releasing 
loaded drug and to study if the microdevices provide a sustained and prolonged release. Ainslie et al. 
investigated if drug is released in a controlled manner from microfabricated devices. Controlled release of 
drug for a prolonged time is often preferred since a sudden ‘burst release’ of the drug can lead to 
unwanted side effects due to the temporarily high dose6. Furthermore, release of two drugs from the same 
microdevice has been investigated as a first step towards multi-drug therapy6. Drug release from the 
microdevices in a liquid environment is often measured by methods such as UV absorbance, fluorescence 
or specialized kits11,12,45,55,56. For visualization of drug release, a UV imager has previously been used. In this 
study, drug release from microwells has been characterized by measuring concentration and 
simultaneously visualizing it over time18. Raman spectroscopy has further been utilized for a qualitative 
measure of the drug release and to investigate the solid state form of the drug when released from the 
microwells18. For better correlation to the in vivo situation, media simulating the fluids in the GI tract have 
often been used in drug release studies11,12,18. In vitro assessment of drug release has the advantage that it 
is relatively fast and therefore very suited for initial investigations before performing cell studies or in vivo 
experiments.    
 
In vitro drug transport and toxicity  
The Caco-2 cell line is, in addition to investigations of bioadhesion, employed to study drug transport 
through cell layers as a measure for intestinal absorption in vivo54. In a study by Ainslie et al., fluorescein 
has been utilized as a model for a small molecule compound and loaded into micropatches. For these 
micropatches, it has been found that fluorescein has been present in high concentration at the cell 
interface resulting in increased drug permeability through the Caco-2 monolayer6. In another study with 
acyclovir, a high local drug concentration provided by the unidirectional release from the micropatches has 
been identified as the reason for an increased drug transport compared to controls10. Furthermore, Gupta 
et al. observed enhanced transport of a model protein, which they speculated to be caused by the 
mucoadhesiveness of the mm-sized patches55. In another study, no significant difference has been 
observed in drug transport, when a drug is confined in microcontainers compared to the free drug11. This 
could be explained by the fact that the tested microcontainers have not been in direct contact with the cell 
layer but were placed in close proximity and therefore, a high local concentration of drug might not have 
been achieved in the same manner as in the other studies.    
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In vivo investigations 
Only a few animal studies on oral delivery using microfabricated devices have so far been published and a 
very few articles have presented specific drug delivery applications. One way to test the in vivo effect is to 
place the devices directly in an intestine and then measure the amount of drug absorbed in the blood56. 
This can be an effective method if the interaction with the intestine should be investigated in details. Gupta 
et al. have used this method to explore the behavior of larger patch-like drug delivery systems with 
different geometries56. For a better correlation to the real life situation of humans ingesting a tablet, it is 
important to orally dose the microdevices. This has been done in mice and rats either by oral gavage10,55 or 
by filling the microdevices into capsules suited for mice and rats followed by oral dosing11,12. Larger animals 
will often give a better correlation to humans51. To our knowledge, no testing of microdevices in larger 
animals has been reported so far.  
SU-8 microcontainers with a diameter of approximately 300 µm25 have proven to increase the oral 
bioavailability of furosemide11 in rats with 220 % over a period of 24 h and of ketoprofen12 with 180 % over 
4 h compared to controls of the drugs not confined in microcontainers. The increased oral bioavailability is 
in both studies explained by the observed microcontainers penetrating into the intestinal mucus. Mazzoni 
et al. dosed the microcontainers orally to rats, followed by optically investigating the stomach and intestine 
after 90 min (Tmax) and only found microcontainers in the small intestine
12.  
In vivo observations are very challenging, and therefore the orientation of microdevices in the intestine has 
so far not been investigated in a satisfactory manner. Hence, it is still not clear if the unidirectional release 
provided by the microdevices is important in an in vivo situation. 
 
Table 2: Overview of the methods and API’s used when testing the microfabricated devices.   
Purpose  Methods Compounds References 
Drug release (in vitro) Fluorescence or UV 
absorption  
Furosemide, ketoprofen, 
ovalbumin, indomethacin, 
Camptothecin, 
Fluorescence-labelled 
albumin,  
insulin 
6,11,12,18,19,45,55,56,58 
Displacement and 
unidirectional release (in 
vitro) 
Caco-2 cells with flow Fluorescein 8 
Bio- and mucoadhesion 
(in vitro) 
Caco-2 or HT-29 cells and  
interaction with devices 
 6,23 
Mucoadhesion (ex vivo) Pig intestine with and 
without flow 
Sodium chloride, 
Fluorescence-labelled 
albumin 
20,53 
 
Mucoadhesion (in situ) Intestinal perfusion in rats  Furosemide 11 
 
Drug transport (in vitro)  Caco-2 cells Fluorescein, furosemide, 
acyclovir 
8,10,11 
Placement (in vivo) Oral administration in rats Ketoprofen 12 
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Oral bioavailability (in 
vivo) 
Oral administration in mice 
and rats 
Furosemide, ketoprofen, 
acyclovir 
10–12 
 
  
 
Discussion and future perspectives  
The field of microfabricated drug delivery devices is rather new and research is still at the proof-of-concept 
stage. However, the past 10 years have shown considerable advances in the fabrication of micropatches, 
microcontainers and similar devices for oral drug delivery and their loading with drug. In the past five years, 
more research groups have been entering the field of microfabricated devices for oral drug delivery and 
focus is now also starting to be on the use of FDA approved materials. Although, initial results have been 
promising, it is still a major challenge to realize microdevices in biocompatible materials and to load these 
microdevices with large amounts of drug. Addressing this issue will in many cases mean development of 
new fabrication routes since these materials are rarely photosensitive. For continuous fabrication of large 
amounts of drug delivery devices, new fabrication routes such as roll-to roll (R2R) and embossing need to 
be explored – both for higher throughput and for non-lithography based processing. In particular, the 
challenge of highly parallel loading of microdevices with reproducible amounts of drug has to be addressed. 
Furthermore in the future, it is important to direct attention on toxicity of these microdevices and to load 
the microdevices only with excipients generally recognized as safe (GRAS).      
Most of the microdevices have so far been rather simple when it comes to overall geometry and surface 
texturing. There are many opportunities for exploring effect of size, shape and surface texture on the flow 
behavior, release profiles and mucoadhesion of the microdevices. Similar studies have previously been 
performed on cm sized tablets fabricated using 3D printing60–62. 
 
There are promising perspectives in microfabricated devices for oral drug delivery demonstrated both by in 
vitro and in vivo studies. However, to date mostly model drugs have been used for evaluation. It is 
essential, to identify relevant applications where major advantages are achieved compared to traditional 
drug delivery systems. Due to the increased fabrication costs, such applications should probably focus on 
therapies requiring low doses and/or where local administration in the GI tract would be beneficial.  
In terms of applications, the delivery of peptides, like insulin, is an interesting target as it could potentially 
help many people confronted with the inconveniences of injections, for example patients with diabetes. 
There is a lot of research and development in making new drug formulations for oral drug delivery of e.g. 
insulin57,59. Microfabricated devices offer an alternative or additional solution to challenges that oral 
delivery is facing. Maybe, by clever design, it is possible to deliver some of the biopharmaceuticals that can 
today not be delivered orally. This might not necessarily require new drug formulations but the loading of 
already existing drugs into miniaturized devices with new properties and new features.  
Another prominent example is oral vaccination, where a microdevice would have potential to carry the 
vaccine formulation to release in proximity of the M-cells (uptake cells). Thereby, the immune cells in the 
small intestine could be activated and create immune responses. Oral vaccination would benefit children in 
vaccination programs both in developing and western countries. Furthermore, compliance would be 
improved for adults getting vaccines due to travel activities63. In addition, microdevices would be beneficial 
where sequential release of drugs is required for examples for HIV compounds. Here, three to four 
compounds often need to be administered simultaneously, and therefore it would be advantageous to 
15 
 
have microdevices where the release is controlled in the order and with the timing desired to have the best 
effect of the drugs64.  
The microdevices are significantly smaller than traditional tablets and the systems for characterization 
should ideally be adapted. Here, lab-on-chip devices can offer a unique platform for drug transport studies 
and release/degradation experiments on minimum amount of material. This has for example been 
demonstrated in the studies of degradation of polymers used in microcontainer fabrication65 and in the 
study of release from individual microcontainers. For future scenarios, it could also be interesting to 
integrate sensors into the drug delivery microdevices. In this way drug release could be triggered by local 
conditions in the GI tract. 
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